ABSTRACT
Aim To investigate the role of 1L-22 / IL- 22BP axis in hepatic ischeniia-reperfusion injury and its potential mechanism.Methods Short, medium, and long-term liver ischemia-reperfusion injury (IKI) and IRI + IL-22 mouse models were established, then the scrum IL-22 concentration, IL-22BP mRNA, IL- 22R a 1 mRNA and STAT3 pathway related protein expression in liver were detected to study the role and mechanism of IL-22 and IL-22 BP in liver IRI.Results Compared with short-term ischemia-reperfusion injury group, mice in middle and long-term ischemia- reperfusion injury groups showed more severe liver injury.The concentration of serum IL-22 significantly increased but the activation of STAT3 pathway was significantly inhibited in long-term ischernia-reperfusion group.The ratio of IL-22BP / IL-22R a 1 niRNA increased significantly with the prolongation of ischemia time.Liver injury was significantly alleviated and the activation of STAT3 pathway was markedly up-regulated after the administration of exogenous recombinant 1L-22 in mice with long-term ischemia-reperfusion injury.Conclusions IL-22 can protect liver from ischemia-reperfusion injur)'; however, IL-22BP / IL-22R a 1 mRNA ratio is a negative indicator of liver injury, and the mechanism may be related to the regulation of STAT3 pathway activation by IL-22 / il-22bp axis dur-ing liver IRI.
ABSTRACT
Background:As the endogenous inhibitor of interleukin(IL)-22,IL-22 binding protein(IL-22BP)inhibits the protective effect of IL-22. Expression and significance of IL-22BP in intestinal mucosa of patients with active inflammatory bowel disease(IBD)remain unclear. Aims:To investigate the expression and significance of IL-22BP in intestinal mucosa of patients with active IBD. Methods:A total of 25 Crohn's disease(CD)and 36 ulcerative colitis(UC)patients from Jan. 2017 to Jan. 2018 at Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine were enrolled, and 30 colonic polyp patients were served as controls. The disease activity of CD and UC was assessed. Expressions of IL-22BP mRNA and protein in intestinal mucosa were determined by real-time fluorescent quantitative PCR and immunohistochemistry,respectively. Correlation of IL-22BP protein expression with the disease activity of CD,UC was analyzed. Results:Compared with corresponding control group,expressions of IL-22BP mRNA in intestinal mucosa in CD and UC groups were significantly increased(CD:3.59 ± 0.83 vs. 1.08 ± 0.45,P<0.001;UC:2.19 ± 0.52 vs. 1.05 ± 0.34,P<0.001),and expressions of IL-22BP protein were also significantly increased(CD:6.12 ± 2.30 vs. 1.83 ± 1.86,P<0.001;UC:5.58 ± 2.27 vs. 2.23 ± 1.77,P<0.001). Expression of IL-22BP protein in intestinal mucosa was positively correlated with disease activity of CD(r =0. 649,P <0. 001)and UC(r =0. 732,P <0.001). Conclusions:Expressions of IL-22BP mRNA and protein are increased in intestinal mucosa of patients with active IBD, and the expression of IL-22BP protein is positively correlated with disease activity of IBD.